CC-90010
Drug
Celgene Corporation
Total Payments
$80,000
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $80,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $80,000 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Testing effects of CC-90010 in GBM models | Celgene Corporation | $80,000 | 0 |
Top Doctors Receiving Payments for CC-90010
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Minneapolis, MN | $80,000 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $80,000
Product Information
- Type Drug
- Total Payments $80,000
- Total Doctors 0
- Transactions 1
About CC-90010
CC-90010 is a drug associated with $80,000 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $80,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for CC-90010 is "Unspecified" ($80,000, 100.0% of total).
CC-90010 is associated with 1 research study, including "Testing effects of CC-90010 in GBM models" ($80,000).